FOURIER

Evolocumab and clinical outcomes in patients with cardiovascular disease - The New England Journal of Medicine - 2017

Brief Summary:

Among patients with clinical atherosclerotic disease and LDL > 70 despite high- or moderate-intensity statin therapy (70% high intensity), the addition of evolocumab resulted in an absolute 1.5% reduction in major cardiovascular events (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) at median follow-up 26 months, driven primarily by reductions in nonfatal MI, stroke, and revascularization. There was no overall or CV-specific mortality benefit with evolocumab. Other than a modest 2% incidence in injection-site reactions, there was no increase in key adverse events including new-onset diabetes or neurocognitive effects in patients receiving evolocumab.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/28304224